Legend Biotech (LEGN) Total Current Liabilities (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Total Current Liabilities data on file, last reported at $509.1 million in Q1 2026.

• Quarterly Total Current Liabilities rose 117.22% year-over-year to $509.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $509.1 million (up 117.22% YoY) and the FY2025 annual result came in at $636.4 million, up 129.17% from the prior year.
• Total Current Liabilities eased to $509.1 million in Q1 2026, from $636.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $636.4 million in Q4 2025 to a low of $175.2 million in Q3 2023.
• A 5-year average of $301.7 million and a median of $265.5 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 154433.99% — and 2023, when it decreased 27.32%.
• Tracing LEGN's Total Current Liabilities over 5 years: stood at $297.8 million in 2022, then dropped by 27.32% to $216.4 million in 2023, then increased by 28.32% to $277.7 million in 2024, then soared by 129.17% to $636.4 million in 2025, then slipped by 20.0% to $509.1 million in 2026.
• The last three Total Current Liabilities figures came in at $509.1 million (Q1 2026), $636.4 million (Q4 2025), and $433.6 million (Q3 2025), per Business Quant data.